First human test of gene therapy for inherited heart disease
NCT ID NCT06109181
Summary
This is a first-in-human study to test the safety and early effectiveness of a new gene therapy called LX2020. It is for adults with a specific genetic form of arrhythmogenic cardiomyopathy, a heart condition that can cause dangerous irregular heartbeats. The therapy is given through an IV and aims to address the underlying genetic cause to help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARRHYTHMOGENIC CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Stanford University
Stanford, California, 94305, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Rochester
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.